Genitourinary Cancers | Specialty

The genitourinary cancers condition center is a comprehensive resource for clinical news and expert insights on genitourinary cancers. Read more at OncLive.

Dr Li on the Casdozokitug/Atezolizumab/Bevacizumab in Unresectable HCC

February 28th 2025

Daneng Li, MD, discusses a trial evaluating casdozokitug plus atezolizumab and bevacizumab in unresectable, locally advanced or metastatic HCC.

Dr Beckermann on the Role of Tivozanib in Advanced Clear Cell RCC

February 28th 2025

Kathryn E. Beckermann, MD, PhD, details the role of tivozanib as second- and third-line therapy in patients with locally advanced or metastatic ccRCC.

Dr Ebrahimi on Clinical Outcomes With the Addition of CBM588 to Cabozantinib and Nivolumab in RCC

February 27th 2025

Hedyeh Ebrahimi, MD, MPH, discusses clinical outcomes with CBM588 plus cabozantinib and nivolumab in metastatic renal cell carcinoma.

Clinical Trials, Randomized Data Are Key to Further Refine Treatment Selection in Advanced Non–Clear Cell RCC

February 27th 2025

Charles B. Nguyen, MD, provides insight into current challenges faced in the non–clear cell RCC landscape beyond the NCCN’s recent guideline updates.

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

February 26th 2025

Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.

Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer

February 25th 2025

Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.

Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC

February 25th 2025

A phase 3 study will be initiated after completion of the first neoadjuvant phase 2 trial of platinum-based chemotherapy plus immunotherapy in UTUC.

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

The OncFive: Top Oncology Articles for the Week of 2/16

February 22nd 2025

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium

February 19th 2025

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

Some Patients With Kidney Cancer Can Stop Combination Treatment After Two Years, Fox Chase Cancer Center Study Finds

February 18th 2025

Some patients with metastatic kidney cancer achieving a good response to a combination therapy can safely stop or pause treatment after 2 years.

European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC

February 18th 2025

The European Commission approved belzutifan for select VHL-associated cancers and advanced clear cell renal cell carcinoma.

Real-World Relugolix Adherence Rates Are High in Patients on Medicare With Prostate Cancer

February 17th 2025

Adherence rates improved the longer patients with metastatic and nonmetastatic prostate cancer received relugolix for a high overall adherence rate.

Dr Merseburger on Real-World Outcomes With First-Line Axitinib Plus Avelumab in RCC

February 16th 2025

Axel Merseburger, MD, PhD, discusses the real-world efficacy and safety of first-line avelumab plus axitinib in advanced renal cell carcinoma.

Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC

February 15th 2025

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

Nivolumab Plus Cabozantinib Provides Durable Benefit in First-Line Advanced RCC

February 15th 2025

Nivolumab in combination with cabozantinib displayed a long-term PFS benefit in patients with treatment-naive advanced RCC.

CBM588 Plus Cabozantinib/Nivolumab Shows Early Activity in Metastatic Renal Cell Carcinoma

February 15th 2025

CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.

Real-World Data Support the Frontline Use of Avelumab Plus Axitinib in Advanced RCC

February 15th 2025

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

Updated Data Support Axitinib Interruption and Avelumab Maintenance After Response in Advanced RCC

February 15th 2025

Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.

Perioperative Lenvatinib Plus Pembrolizumab Is Safe and Effective in Advanced ccRCC

February 15th 2025

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.